An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).
J. H. Machiels(Semmelweis University), Paul M. Clément(Universitair Ziekenhuis Leuven), Annika Flygare(Genmab (Denmark)), Gábor Répássy(Semmelweis University), I. Lifrenko(Semmelweis University), Ágnes Ruzsa(Baranya Megyei Kórház), Peter G. Sørensen(Leiden University Medical Center), E. Ehrnrooth(Boehringer Ingelheim (Germany)), O Baadsgaard(Semmelweis University), S. Subramanian(Semmelweis University)
Cited by 13
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445
Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer
|Journal of Clinical Oncology|2000|443